Epoxomicin is a naturally occurring selective proteasome inhibitor with anti-inflammatory activity.[2] It was originally discovered in 1992.[3] Injected, it can induce Parkinson's-like symptoms in rats.

Epoxomicin[1]
Names
IUPAC name
(2S,3S)-N-((2S,3R)-3-hydroxy-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxobutan-2-yl)-3-methyl-2-((2S,3S)-3-methyl-2-(N-methylacetamido)pentanamido)pentanamide
Other names
BU 4061T
Identifiers
3D model (JSmol)
ChEMBL
UNII
  • O=C([C@@]1(C)CO1)[C@H](CC(C)C)NC([C@@H](NC([C@H]([C@@H](C)CC)NC([C@H]([C@@H](C)CC)N(C)C(C)=O)=O)=O)[C@H](O)C)=O
Properties
C28H50N4O7
Molar mass 554.729 g·mol−1
Appearance White solid
Solubility in DMSO 10 mg/mL
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Derivatives of epoxomicin include carfilzomib.

References

edit
  1. ^ Epoxomicin, Santa Cruz Biotechnology
  2. ^ Meng, L; Mohan, R; Kwok, BH; Elofsson, M; Sin, N; Crews, CM (1999). "Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity". PNAS. 96 (18): 10403–10408. doi:10.1073/pnas.96.18.10403. PMC 17900. PMID 10468620.
  3. ^ Epoxomicin, Peptide Institute, Inc.

Further reading

edit